Abstract
The largest phase 2 study done to date in patients with platelet-derived growth factor β (PDGFβ)-positive advanced chordoma treated with imatinib (800 mg daily), failed to elicit an overall tumour response defined by RECIST. However, at 6 months, 70% of patients remained stable during treatment, 64% showed a clinical benefit, and 18% showed some reduction in tumour size. “Although the responses were not dramatic, nearly two-thirds of chordoma patients benefited from imatinib treatment. For a disease with few other treatment options and no approved drugs, these results are significant”, comments Josh Sommer, from the Chordoma Foundation (Durham, NC, USA).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
